NovoCure Limited (NVCR) Research

NovoCure Limited operates as an oncology enterprise specializing in the development, manufacturing, and global commercialization of its proprietary Tumor Treating Fields (TTFields) technology. These innovative devices are engineered to treat solid tumor cancers, with the company's market presence spanning the United States, Europe, the Middle East, Africa, Japan, and Greater China. The company's commercialized offerings include Optune, which is indicated for glioblastoma, and Optune Lua, approved for use in malignant pleural mesothelioma. Beyond these established treatments, NovoCure actively conducts, or has completed, clinical research into the potential applications of TTFields for a broader spectrum of cancers. These investigational areas encompass brain metastases, gastric cancer, further studies in glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. Founded in 2000, NovoCure Limited is headquartered in Saint Helier, Jersey.

Market snapshot

Symbol
NVCR
Price
$14.28
Day change
-20.00%
Market cap
$1.7B
P/E ratio
-9.42x
52-week range
9.82-18.92
Sector
Healthcare
Industry
Medical - Instruments & Supplies
Next earnings
in 1 month
Analyst price target
$33.00

Recent news

  • Novocure's cancer treatment fails to meet late-stage trial goal

    Novocure ​said on ‌Thursday ​that ​its cancer ⁠treatment ​for ​newly diagnosed brain ​tumors ​did not ‌meet ⁠the main ​goal ​of ⁠a ​late-stage ​study.

  • NovoCure Tumor Treating Fields Shows Improved Outcomes In Tough Pancreatic Cancer

    The stock is gaining traction as the company reported a disease control rate of 74.4%, significantly higher than the historical control of 48%.

Peer companies

  • Azenta, Inc. (AZTA)
  • BioLife Solutions, Inc. (BLFS)
  • Establishment Labs Holdings Inc. (ESTA)
  • Evotec SE (EVO)
  • Kestra Medical Technologies, Ltd. (KMTS)
  • Neogen Corporation (NEOG)
  • Pulse Biosciences, Inc. (PLSE)
  • STAAR Surgical Company (STAA)

Recent insider activity

  • Leonard Frank X — S-Sale (34273 shares) on 2026-06-04
  • LEUNG GABRIEL — A-Award (11610 shares) on 2026-06-03
  • LEUNG GABRIEL — A-Award (16999 shares) on 2026-06-03
  • Stafford Kristin — A-Award (11610 shares) on 2026-06-03
  • Stafford Kristin — A-Award (16999 shares) on 2026-06-03

Open NovoCure Limited (NVCR) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.